Kyverna Therapeutics 주식 (NASDAQ: KYTX)

에 대한 최신 뉴스 Kyverna Therapeutics (NASDAQ:KYTX) 주식

Kyverna Therapeutics

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Wall Street US stocks

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

KYTX

PSFE

RMBL

화요일 오전(현지 시간 기준) 미국 주식 선물이 상승하면서 오늘 투자자들의 관심을 끌 수 있는 주식 중 일부는 다음과 같다: 월가는 홈 디포(NYSE:HD)가 개장 전에 분기별 이익을 주당 4.50달러, 매출 433억 8천만 달러로 보고할 것으로 예상하고 있다. 홈디포 주가는 시간외 거래에서 0.2% 상승한 346.59달러를 기록했다.

화요일 주목해야 할 주식: 홈 디포, 페이세이프 그리고 3종목

Bank,Of,America,In,Beverly,Hills

Equities

화요일 오전 (미 동부 시간 기준) 미국 주식 선물이 상승하면서 오늘 투자자의 관심을 끌 수 있는 주식 중 일부는 다음과 같다: 월스트리트는 뱅크 오브 아메리카(NYSE:BAC)가 개장 전에 252억 2천만 달러의 매출과 주당 80센트의 분기 이익을 보고할 것으로 예상하고 있다. 뱅크 오브 아메리카의 주식은 시간외 거래에서 0.1% 상승한 41.94달러를 기록했다. 

화요일 주목해야 할 주식: 뱅크 오브 아메리카, 모건 스탠리 그리고 3종목

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics Inc

Goldman Sachs analyst Matthew Sykes maintains Cytek Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) with a Sell and lowers the price target from $3.5 to $3.

Price Target

Analyst Ratings

CTKB

Goldman Sachs Maintains Sell on Cytek Biosciences, Lowers Price Target to $3

WIIM

Dr. Reddy's Laboratories shares are trading hgher on possible continued strength after reporting better-than-expected Q4 financial results on Friday.

CPSS

CORRECTION: Consumer Portfolio Services Announces The Closing Of A $419.95M Senior Subordinate Asset-Backed Securitization

ADNT

APTV

FOXF

HLLY

LAZR

LCID

MBLY

PATK

RIVN

TSLA

Shares of auto and auto parts stocks are trading higher after the US and China agreed to a temporary reduction in most tariffs on each other's goods. This could alleviate supply chain uncertainty in the sector.

Whales with a lot of money to spend have taken a noticeably bullish stance on HubSpot.
Looking at options history for HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 72% of the investors opened trades with bullish expectations and 0% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $1,002,330 and 8, calls, for a total amount of $355,075.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $480.0 to $640.0 for HubSpot during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for HubSpot options trades today is 52.75 with a total volume of 278.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for HubSpot's big money trades within a strike price range of $480.0 to $640.0 over the last 30 days.
<h3>HubSpot Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747069356_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUBS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$28.0</td>
<td>$21.9</td>
<td>$21.9</td>
<td>$480.00</td>
<td>$334.1K</td>
<td align="right">2</td>
<td align="right">150</td>
</tr>
<tr>
<td>HUBS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$28.0</td>
<td>$21.9</td>
<td>$21.9</td>
<td>$480.00</td>
<td>$334.1K</td>
<td align="right">2</td>
<td align="right">150</td>
</tr>
<tr>
<td>HUBS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$28.0</td>
<td>$21.9</td>
<td>$21.9</td>
<td>$480.00</td>
<td>$334.1K</td>
<td align="right">2</td>
<td align="right">150</td>
</tr>
<tr>
<td>HUBS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$21.6</td>
<td>$19.5</td>
<td>$21.6</td>
<td>$610.00</td>
<td>$64.8K</td>
<td align="right">85</td>
<td align="right">44</td>
</tr>
<tr>
<td>HUBS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$21.6</td>
<td>$19.5</td>
<td>$21.6</td>
<td>$610.00</td>
<td>$64.8K</td>
<td align="right">85</td>
<td align="right">44</td>
</tr>
</tbody>
</table>

<h3>About HubSpot</h3>
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
In light of the recent options history for HubSpot, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of HubSpot</h3>
<ul>
<li>With a trading volume of 611,717, the price of HUBS is up by 8.34%, reaching $653.32.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 86 days from now.</li>
</ul>
<h3>Expert Opinions on HubSpot</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $769.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for HubSpot, targeting a price of $750. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on HubSpot, which currently sits at a price target of $752. 
&#x2A; Reflecting concerns, an analyst from Raymond James lowers its rating to Outperform with a new price target of $825. 
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Buy rating on HubSpot with a target price of $700. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on HubSpot with a target price of $820. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest HubSpot options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

HUBS

HubSpot's Options Frenzy: What You Need to Know

Goldman Sachs analyst James Yaro maintains Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Neutral and raises the price target from $189 to $209.

COIN

Goldman Sachs Maintains Neutral on Coinbase Global, Raises Price Target to $209

Investors with a lot of money to spend have taken a bullish stance on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with ABBV, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for AbbVie.
This isn't normal.
The overall sentiment of these big-money traders is split between 62% bullish and 37%, bearish.
Out of all of the options we uncovered, 7 are puts, for a total amount of $806,471, and there was 1 call, for a total amount of $65,475.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $185.0 for AbbVie over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in AbbVie's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to AbbVie's substantial trades, within a strike price spectrum from $150.0 to $185.0 over the preceding 30 days.
<h3>AbbVie 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747069351_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$0.9</td>
<td>$0.71</td>
<td>$0.88</td>
<td>$180.00</td>
<td>$440.0K</td>
<td>12.2K</td>
<td>10.2K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$0.39</td>
<td>$0.08</td>
<td>$0.18</td>
<td>$170.00</td>
<td>$108.0K</td>
<td>11.1K</td>
<td>10.3K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$0.86</td>
<td>$0.71</td>
<td>$0.88</td>
<td>$180.00</td>
<td>$88.0K</td>
<td>12.2K</td>
<td>10.2K</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$43.65</td>
<td>$42.4</td>
<td>$43.65</td>
<td>$150.00</td>
<td>$65.4K</td>
<td>125</td>
<td>0</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$8.7</td>
<td>$8.6</td>
<td>$8.6</td>
<td>$185.00</td>
<td>$56.7K</td>
<td>737</td>
<td>137</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Having examined the options trading patterns of AbbVie, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is AbbVie Standing Right Now?</h3>
<ul>
<li>With a trading volume of 6,249,708, the price of ABBV is up by 3.85%, reaching $191.72.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 73 days from now.</li>
</ul>
<h3>What The Experts Say On AbbVie</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $219.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for AbbVie, targeting a price of $205. 
&#x2A; Reflecting concerns, an analyst from Guggenheim lowers its rating to Buy with a new price target of $214. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for AbbVie, targeting a price of $250. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $210. 
&#x2A; An analyst from Guggenheim persists with their Buy rating on AbbVie, maintaining a target price of $216. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

ABBV

AbbVie Unusual Options Activity

Deep-pocketed investors have adopted a bullish approach towards ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NOW usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 28 extraordinary options activities for ServiceNow. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 64% leaning bullish and 17% bearish. Among these notable options, 5 are puts, totaling $143,900, and 23 are calls, amounting to $1,279,762.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $800.0 to $1500.0 for ServiceNow during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for ServiceNow's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ServiceNow's whale trades within a strike price range from $800.0 to $1500.0 in the last 30 days. 
<h3>ServiceNow Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747069346_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$289.6</td>
<td>$278.0</td>
<td>$286.0</td>
<td>$890.00</td>
<td>$286.0K</td>
<td align="right">35</td>
<td align="right">10</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$156.5</td>
<td>$149.9</td>
<td>$152.8</td>
<td>$900.00</td>
<td>$152.8K</td>
<td align="right">127</td>
<td align="right">10</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$103.0</td>
<td>$102.0</td>
<td>$102.0</td>
<td>$930.00</td>
<td>$102.0K</td>
<td align="right">47</td>
<td align="right">10</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$140.8</td>
<td>$136.6</td>
<td>$138.7</td>
<td>$920.00</td>
<td>$69.3K</td>
<td align="right">72</td>
<td align="right">5</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$25.9</td>
<td>$19.3</td>
<td>$24.0</td>
<td>$1300.00</td>
<td>$60.0K</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About ServiceNow</h3>
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.
Following our analysis of the options activities associated with ServiceNow, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of ServiceNow</h3>
<ul>
<li>Trading volume stands at 605,369, with NOW's price up by 3.01%, positioned at $1009.54.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 72 days.</li>
</ul>
<h3>What The Experts Say On ServiceNow</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $1096.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from JMP Securities downgraded its rating to Market Outperform, setting a price target of $1300. 
&#x2A; An analyst from Scotiabank has decided to maintain their Sector Outperform rating on ServiceNow, which currently sits at a price target of $1075. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on ServiceNow with a target price of $969. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on ServiceNow with a target price of $1020. 
&#x2A; An analyst from Piper Sandler has decided to maintain their Overweight rating on ServiceNow, which currently sits at a price target of $1120. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for ServiceNow, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

ServiceNow's Options: A Look at What the Big Money is Thinking

CNH Industrial shares are trading higher after UBS raised its price target on the stock from $13 to $16.

Wells Fargo analyst Finian O'Shea maintains Prospect Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSEC#NASDAQ">PSEC</a>) with a Underweight and lowers the price target from $3.5 to $3.

PSEC

Wells Fargo Maintains Underweight on Prospect Capital, Lowers Price Target to $3

ACDC

ARIS

CHRD

CIVI

CLNE

CRGY

FANG

GPRE

LBRT

PTEN

PUMP

TRGP

VIST

WFRD

Shares of energy stocks are trading higher amid a rise in the price of oil after the US and China agreed to a temporary reduction in most tariffs. The commodity may be experiencing strength amid escalating conflict between Pakistan and India.

WTRG

Essential Utilities shares are trading lower following Q1 financial results.

Goldman Sachs analyst Mike Harris maintains Cleveland-Cliffs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) with a Buy and lowers the price target from $13 to $11.25.

Goldman Sachs Maintains Buy on Cleveland-Cliffs, Lowers Price Target to $11.25

In the current session, the stock is trading at $31.47, after a 1.16% increase. Over the past month, Enterprise Prods Partners Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) stock increased by 2.08%, and in the past year, by 9.06%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1747069257_0.png" alt="Past Year Chart" />

<h3>Enterprise Prods Partners P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 19.96 in the Oil, Gas &amp; Consumable Fuels industry, Enterprise Prods Partners Inc. has a lower P/E ratio of 11.65. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747069257_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

P/E Ratio Insights for Enterprise Prods Partners

Wells Fargo analyst Richard Garchitorena maintains CF Industries Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) with a Overweight and raises the price target from $96 to $98.

Wells Fargo Maintains Overweight on CF Industries Holdings, Raises Price Target to $98

AMZN

CNBC Halftime Report Final Trades: Citigroup, Truist Financial, Amazon

Estee Lauder Cos's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) short percent of float has risen 8.15% since its last report. The company recently reported that it has 8.95 million shares sold short, which is 3.85% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.43 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Estee Lauder Cos Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747069233_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Estee Lauder Cos has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Estee Lauder Cos's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Estee Lauder Cos's peer group average for short interest as a percentage of float is 5.85%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Estee Lauder Cos?

Avient's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVNT#NYSE">AVNT</a>) short percent of float has fallen 3.77% since its last report. The company recently reported that it has 1.77 million shares sold short, which is 2.55% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Avient Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747069227_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Avient has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Avient's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Avient's peer group average for short interest as a percentage of float is 4.41%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

AVNT

Is Avient Gaining or Losing Market Support?

CSX's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NYSE">CSX</a>) short percent of float has fallen 7.32% since its last report. The company recently reported that it has 28.55 million shares sold short, which is 1.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.7 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>CSX Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747069221_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for CSX has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing CSX's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, CSX's peer group average for short interest as a percentage of float is 9.37%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is the Market Bullish or Bearish on CSX?

Goldman Sachs analyst Michael Ng maintains Blend Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>) with a Buy and lowers the price target from $5.6 to $4.8.

BLND

Goldman Sachs Maintains Buy on Blend Labs, Lowers Price Target to $4.8

Press Releases

Investors in Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Legal

Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf

Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf

Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your Behalf

Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Claims on Your Behalf

Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

ALERT: Grabar Law Office Investigates Claims for Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); and Virtu Financial, Inc. (NASDAQ: VIRT)

Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your Behalf

AKRO

DRVN

EMPW

FLNC

IART

MODV

MPWR

MRCY

RKLB

SAGE

VIRT

Anixa Biosciences

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

C4 Therapeutics

Coya Therapeutics

Elicio Therapeutics

Elutia

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

HilleVax

Immunic

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Lexeo Therapeutics

Macrogenics

OncoCyte

ProKidney Corp. - Class A Ordinary Shares

ProKidney

RAPT Therapeutics

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Senti Biosciences

Instil Bio

Vaxart

XBiotech

Exagen

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Zura Bio Limited - Class A Ordinary shares

Zura Bio

HC Wainwright & Co.

Morgan Stanley

Wells Fargo

JP Morgan

화요일 오전(현지 시간 기준) 미국 주식 선물이 상승하면서 오늘 투자자들의 관심을 끌 수 있는 주식 중 일부는 다음과 같다:
<ul>
<li>월가는 홈 디포(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>)가 개장 전에 분기별 이익을 주당 4.50달러, 매출 433억 8천만 달러로 보고할 것으로 예상하고 있다. 홈디포 주가는 시간외 거래에서 0.2% 상승한 346.59달러를 기록했다.</li>
<li>럼블온(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>)은 2분기 매출은 2,250만 달러로 전 분기 대비 27% 증가했다. Benzinga Pro의 데이터에 따르면 매출 수치는 월가의 컨센서스 추정치인 1,969만 달러를 넘어섰다. 이 회사는 주당 13센트의 손실을 보고했는데, 이는 월가의 컨센서스인 주당 15센트의 손실을 능가하는 것이다. 럼블의 주식은 월요일에 0.3% 하락한 3.42달러로 마감했다.</li>
<li>분석가들은 페이세이프(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>)가 4억 2,429만 달러의 매출에 주당 8센트의 분기 수익을 기록할 것으로 예상하고 있다. 이 회사는 시장이 개장 전에 실적을 발표할 예정이다. 페이세이프의 주식은 시간외 거래에서 2.6% 상승한 19.86달러를 기록했다.</li>
</ul>
여기에서 <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noopener" data-google-interstitial="false">프리마켓 시황</a>을 확인하세요.
<ul>
<li>카이버나 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>)는 진행성 중증 근무력증 치료에 사용되는 KYV-101에 대해 미국 FDA RMAT 지정을 받았다고 밝혔다. 카이버나 테라퓨틱스의 주가는 시간외 거래에서 2.9% 상승한 6.72달러를 기록했다.</li>
<li>분석가들은 XP(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XP#NASDAQ">XP</a>)가 시장 마감 후 7억 7,039만 달러의 매출과 주당 36센트의 분기 이익을 기록할 것으로 예상한다. XP의 주가는 월요일에 0.2% 하락한 18.03달러로 마감했다.</li>
</ul>
Photo courtesy: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

화요일 오전 (미 동부 시간 기준) 미국 주식 선물이 상승하면서 오늘 투자자의 관심을 끌 수 있는 주식 중 일부는 다음과 같다:
<ul>
<li>월스트리트는 뱅크 오브 아메리카(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>)가 개장 전에 252억 2천만 달러의 매출과 주당 80센트의 분기 이익을 보고할 것으로 예상하고 있다. 뱅크 오브 아메리카의 주식은 시간외 거래에서 0.1% 상승한 41.94달러를 기록했다.</li>
<li>FB 파이낸셜(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBK#NYSE">FBK</a>)은 월요일에 예상보다 나은 2분기 실적을 발표했다. FB 금융 주가는 시간외 거래에서 0.5% 상승한 43.03달러를 기록했다.</li>
<li>분석가들은 모건 스탠리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>)가 매출 143억 달러, 주당 1.65달러의 분기 이익을 기록할 것으로 예상하고 있다. 이 회사는 시장이 열리기 전에 수익을 발표할 예정이다. 모건 스탠리의 주가는 시간외 거래에서 0.8% 상승한 106.14달러를 기록했다.</li>
</ul>
당사의 <a href="https://www.benzinga.com/premarket/">프리마켓 시장 뉴스를 확인하세요.</a>
<ul>
<li>카이버나 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>)는 불응성 강직증후군 환자 치료에 대해 KYV-101이 FDA 재생의학 첨단치료제로 지정되었다고 발표한 후 월요일 시간외 거래에서 급등했다. 카이버나의 주가는 시간외 거래에서 7.5% 상승한 10.65달러를 기록했다.</li>
<li>분석가들은 유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)가 시장 마감 후 988억 4천만 달러의 매출과 주당 6.66달러의 분기 이익을 발표할 것으로 예상한다. 유나이티드헬스의 주가는 시간외 거래에서 0.9% 상승한 519.99달러를 기록했다.</li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Kyverna Therapeutics

뉴스

에 대한 최신 뉴스 Kyverna Therapeutics (NASDAQ:KYTX) 주식

화요일, 8월 13, 2024

화요일, 7월 16, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌